Zymfentra Kit
NDC Package 72606-025-06
Package Information
Zymfentra (infliximab-dyyb) kits is a medication used to treat certain types of arthritis (rheumatoid arthritis, arthritis of the spine, psoriatic arthritis), certain bowel diseases (Crohn's disease, ulcerative colitis), and a certain severe skin disease (chronic plaque psoriasis). This formulation utilizes a kit delivery system. Marketed by Celltrion Usa Inc., this product is identified by NDC 72606-025 and is authorized under FDA application BLA761358.
Identification & Billing
- RxCUI: 2675742 - inFLIXimab-dyyb 120 MG in 1 ML Pen Injector
- RxCUI: 2675742 - 1 ML infliximab-dyyb 120 MG/ML Pen Injector
- RxCUI: 2675742 - infliximab-dyyb 120 MG per 1 ML Pen Injector
- RxCUI: 2675749 - Zymfentra 120 MG in 1 ML Pen Injector
- RxCUI: 2675749 - 1 ML infliximab-dyyb 120 MG/ML Pen Injector [Zymfentra]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 72606 - Celltrion Usa Inc.
- 72606-025 - Zymfentra
- 72606-025-06 - 2 KIT in 1 CARTON / 1 KIT in 1 KIT * 1 SYRINGE in 1 TRAY / 1 mL in 1 SYRINGE * 1 mL in 1 PACKET
- 72606-025 - Zymfentra
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (72606-025). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 72606-025-06 identifies a specific commercial package of 2 kit in 1 carton / 1 kit in 1 kit * 1 syringe in 1 tray / 1 ml in 1 syringe * 1 ml in 1 packet of Zymfentra, a human prescription drug labeled by Celltrion Usa Inc.. This kit is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Celltrion Usa Inc. on March 01, 2024. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat certain types of arthritis (rheumatoid arthritis, arthritis of the spine, psoriatic arthritis), certain bowel diseases (Crohn's disease, ulcerative colitis), and a certain severe skin disease (chronic plaque psoriasis). In these conditions, the body's defense system (immune system) attacks healthy tissues. Infliximab works by blocking the actions of a certain natural substance (tumor necrosis factor alpha) in the body. This helps to decrease swelling (inflammation) and weaken your immune system, which slows or stops the damage from the disease. This monograph is about the following infliximab products: infliximab, infliximab-abda, infliximab-axxq, and infliximab-dyyb.
How is this Celltrion Usa Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 72606002506. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
